At Microbia PE, our business is all about developing highly productive, low-cost bioprocesses. We bring these innovations to market in several ways:
Developing and commercializing our own products Our team has developed a novel production platform for "lipophilic chemicals"—fat-loving compounds that currently represent an aggregate commercial opportunity of approximately $2 billion. The first of these products is currently undergoing process development and scale-up. Learn more.
Cooperative alliances with strategic partners Microbia PE also identifies strategic partners with complementary capabilities to jointly develop and commercialize products. For example, we formed a partnership in 2006 with Tate & Lyle, a world leader in renewable ingredients, to develop and commercialize new fermentation-derived products. Learn more.
Providing process development services to other partners With our specialized expertise in biomanufacturing technology, Microbia PE is a sought-after resource among companies that want to develop or improve microbial production systems. In the past few years, we've provided these services to a variety of organizations, including DuPont, Ranbaxy Laboratories, Novus International, and Biocon. Learn more.